| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | NaN | 36,751 | NaN | NaN |
| Manufacturing cost of sales | NaN | 9,845 | NaN | NaN |
| Profit share and royalties in cost of sales | NaN | 2,192 | NaN | NaN |
| Research and development | NaN | 7,272 | NaN | NaN |
| Sales and marketing | NaN | 4,590 | NaN | NaN |
| General and administrative | NaN | 2,460 | NaN | NaN |
| Other segment items | NaN | -931 | NaN | NaN |
| Interest income | NaN | 408 | NaN | NaN |
| Interest expense, net | NaN | 2,755 | NaN | NaN |
| Total revenues | -10,118 | NaN | 9,557 | 9,179 |
| Manufacturing cost of sales | -2,812 | NaN | 2,508 | 2,484 |
| Profit share and royalties in cost of sales | -537 | NaN | 574 | 527 |
| Research and development | -1,925 | NaN | 1,900 | 1,744 |
| Sales and marketing | -1,100 | NaN | 1,097 | 1,137 |
| General and administrative | -709 | NaN | 623 | 554 |
| Other segment items | 1,016 | NaN | -1,642 | 539 |
| Equity in (income) loss of equity method investments | NaN | NaN | 10 | -18 |
| Interest income | -84 | NaN | 99 | 86 |
| Interest expense, net | -722 | NaN | 685 | 694 |
| Provision for income taxes | 265 | 181 | 705 | 136 |
| Net income | 1,819 | 1,333 | 3,216 | 1,432 |
| Depreciation, amortization and other | 1,116 | 1,132 | 1,307 | 1,341 |
| Impairment of intangible assets | 0 | 0 | 400 | 0 |
| Stock-based compensation expense | 75 | 125 | 127 | 157 |
| Deferred income taxes | -176 | -19 | -30 | -422 |
| Loss (gain) on equity securities | -143 | -648 | 1,971 | -554 |
| Other items, net | 67 | -250 | 28 | 23 |
| Trade receivables, net | -413 | 1,075 | -222 | 515 |
| Inventories | -18 | -119 | -240 | -239 |
| Other assets | -8 | 577 | 283 | 206 |
| Accounts payable | 571 | -484 | -174 | 589 |
| Accrued income taxes, net | 71 | -365 | 610 | -2,417 |
| Long-term tax liabilities | 71 | 75 | 74 | 92 |
| Accrued liabilities | -959 | 749 | -200 | 824 |
| Accrued sales incentives and allowance | -839 | -232 | 1,184 | 627 |
| Other liabilities | -75 | -76 | -10 | 8 |
| Net cash provided by operating activities | 2,189 | 1,603 | 4,684 | 2,280 |
| Cash paid for acquisitions, net of cash acquired | NaN | 53 | NaN | NaN |
| Proceeds from sales of marketable securities | NaN | 0 | NaN | NaN |
| Proceeds from maturities of marketable securities | NaN | 0 | NaN | NaN |
| Purchases of property, plant and equipment | 712 | 642 | 436 | 369 |
| Other | 4 | -2 | -22 | 20 |
| Net cash used in investing activities | -716 | -693 | -414 | -389 |
| Net proceeds from issuance of debt | 3,964 | 0 | NaN | NaN |
| Extinguishment of debt | 233 | 0 | 81 | 301 |
| Repayment of debt | 833 | 0 | 1,500 | 1,000 |
| Repurchases of common stock | NaN | 0 | NaN | NaN |
| Dividends paid | 1,358 | 1,283 | 1,282 | 1,280 |
| Other | -104 | 57 | 10 | -92 |
| Net cash provided by (used in) financing activities | 1,436 | -1,226 | -2,853 | -2,673 |
| Increase (decrease) in cash and cash equivalents | 2,909 | -316 | 1,417 | -782 |
| Cash and cash equivalents at beginning of period | 9,129 | 9,445 | 8,028 | 8,810 |
| Cash and cash equivalents at end of period | 12,038 | 9,129 | 9,445 | 8,028 |
AMGEN INC (AMGN)
AMGEN INC (AMGN)